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Over the past two and a half decades, a remarkable series of
tools, technologies, and techniques have been created,
developed, and refined for the performance of percutaneous
coronary intervention (PCI). A constant over time, how-
ever, has been the therapeutic framework of enlargement of
the luminal dimensions of diseased coronary vessels as the
hallmark of PCI. Within this construct, an obligatory
disruption of the integrity of the vascular endothelium and
other vessel components is produced. An inherent and
inevitable consequence of PCI is, thus, the creation of a
local environment conducive to thrombosis.
See page 1188
In parallel with developments in the technology of PCI
has been the detailed elucidation of platelet physiology,
coupled with a deeper understanding of the role of the
platelet in the thrombosis cascade (1,2). The complexities of
the platelet can be distilled into several overlapping func-
tions: adhesion, activation, secretion, and aggregation. In
the setting of PCI, numerous clinical trials have established
the independent efficacies of agents that target the platelet,
namely aspirin, the thienopyridines, and platelet glycopro-
tein (GP) IIb/IIIa receptor blockers (3–8). Classified by
their respective targets, aspirin inhibits platelet activation via
the irreversible acetylation of cyclooxygenase and conse-
quent suppression of the synthesis of thromboxane A2, a
potent platelet stimulant. The thienopyridines (ticlopidine
and clopidogrel) also irreversibly inhibit platelet activation,
albeit via a different pathway, blockade of the P2T type
adenosine diphosphate (ADP) receptor (9). Adenosine
diphosphate modulates the change of the GP IIb/IIIa
receptor from an inactive, inert state to a ligand receptive
conformation. The platelet GP IIb/IIIa receptor antagonists
inhibit platelet aggregation via blockade of the RGD-
specific binding site for fibrinogen and other adhesion
molecules to the IIb/IIIa integrin on platelets (10). Since
activation is a prerequisite to secretion and aggregation,
both aspirin and the thienopyridines (partially) inhibit these
functions; conversely, GP IIb/IIIa blockade indirectly re-
duces platelet secretion by reducing platelet mass while
having little direct effect on platelet activation.
Rather than clarifying the landscape, clinical trials of
antiplatelet therapies have led to a bewildering array of
uncertainties regarding the appropriate selection, timing,
and duration of the various treatment options. Although
there is universal acceptance of aspirin as a mainstay of
treatment, less certain are the answers about clopidogrel and
the GP IIb/IIIa antagonists. With respect to clopidogrel
therapy as an adjunct to contemporary PCI, the key remain-
ing questions include the following. First, what is the
optimal timing of the initiation of thienopyridine therapy
relative to the start of a PCI procedure—along with the
corollary question, is ad hoc treatment (i.e., on the cathe-
terization table during a “cath possible” case) as good as
several hours (or days) of pretreatment? Second, what is
actually being accomplished with clopidogrel pretreat-
ment—again with a corollary question, is post-treatment
(after PCI) effective in preventing subacute stent thrombo-
sis? Third, can a thienopyridine be used as a substitute for a
GP IIb/IIIa integrin antagonist (and vice versa), or are these
agents complementary and best used concurrently? Fourth,
what is the appropriate loading dose of clopidogrel, partic-
ularly in the ad hoc situation? And fifth, how long should
clopidogrel be administered after the procedure?
In this issue of the Journal, Chan et al. (11) have
addressed the first three of these key questions. A series of
post hoc analyses of the 4,809-patient TARGET (Do
Tirofiban and ReoPro Give Similar Efficacy Outcomes
Trial) study of tirofiban versus abciximab in stent PCI (12)
were conducted, incorporating statistical approaches to ad-
just and account for differences among groups. The key
findings have a high degree of relevance to the practice of
contemporary stent PCI.
With respect to the first question (timing of clopidogrel
relative to intervention), outcomes of patients were im-
proved with the administration of a 300-mg loading dose of
clopidogrel when given at any time before the PCI proce-
dure (including just before the procedure) relative to the
subgroup that had clopidogrel started after PCI. In this
report, the majority (57%) of patients who were pretreated
received drug within 2 h of PCI, with only 16% of
pretreated patients having received clopidogrel 6 h before
PCI. The benefit of 6 h of pretreatment was marginal
relative to treatment for 6 h, suggesting a slight, but
perhaps still meaningful, additional advantage to a longer
period of pretreatment before PCI.
The crucial point of the analysis is that benefit is greatest
when clopidogrel is started before PCI. This is consistent
with both the pathophysiology of PCI (wherein a relatively
inert blood vessel is abruptly converted into a prothrombotic
milieu) and the rapid bioavailability of the active metabolite
of clopidogrel, generally within minutes of drug adminis-
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tration (13–15). Delaying treatment until after PCI has
been completed (i.e., after activation of the thrombosis
cascade) would seem somewhat imprudent, particularly
because administration even in an ad hoc fashion is not
especially difficult. Coupled with the known liabilities of
clopidogrel treatment vis a´ vis the excessive rates of bleeding
in the patient undergoing coronary artery bypass surgery,
(16,17), this would argue for pretreatment of patients posted
for elective PCI who have already undergone diagnostic
catheterization, and for the ad hoc treatment of “cath
possible” patients who may (or may not) subsequently
undergo PCI.
These data are thus both congruous and expand upon the
results of the recent PCI-CURE (Clopidogrel in Unstable
Angina to Prevent Recurrent Events) and CREDO (Clo-
pidogrel for the Reduction of Events During Observation)
trials (6,16). In these studies, patients undergoing PCI were
randomized to treatment with clopidogrel for either several
days (PCI-CURE) or 3 to 24 h (CREDO) before PCI and
were found to have 30% (p  0.03) and 18.5% (p  0.23)
relative risk reductions in the composite of death, myocar-
dial infarction (MI), or urgent target vessel revascularization
(TVR) to 28 days, respectively, compared with those started
on clopidogrel after PCI. The unique contribution of the
current work is the efficacy observed in the large group of
patients treated within 0 to 2 h before PCI, a group
heretofore left unstudied in randomized clinical trials. This
compelling observation speaks to the absence of a specific
trial addressing the question of ad hoc treatment; a random-
ized clinical trial comparing6 h of treatment versus ad hoc
treatment (perhaps with 300 mg vs. 600 mg dosing sched-
ules) would seem to be in order to verify these post hoc
findings.
A mild damper on the pro forma conclusions to the first
question relates to the second question (characterization of
the benefits of clopidogrel treatment). In the mid 1990s, the
wholesale substitution of thienopyridine therapy for warfa-
rin anticoagulation after stent PCI was driven largely by
reductions in bleeding and subacute stent thrombosis (18–
21). However, most of the efficacy of pretreatment with
clopidogrel in the current study was in reducing death or
MI. There were no reported differences in rates of urgent
TVR between the pretreatment and post-treatment groups,
suggesting that subacute stent thrombosis is an infrequent
event that can be suppressed by administration of clopi-
dogrel as long as it is started around the time (either before
or immediately following) of PCI. If the goal is thus to
simply prevent subacute stent thrombosis, the timing of
clopidogrel administration would appear to be less relevant
provided a 300-mg loading dose is administered shortly
after PCI. However, this would be obviating the potential
benefits of reducing death or MI simply as a matter of
convenience and would overall seem ill advised.
Finally, the third question (the relative contributions of
clopidogrel and platelet GP IIb/IIIa blockade to reducing
ischemic complications) can be inferentially approached by
examining the current study in the context of the existing
literature. Pretreatment with clopidogrel provided addi-
tional efficacy to patients already receiving a GP IIb/IIIa
inhibitor in the TARGET trial. The converse was ad-
dressed in two other studies, the Evaluation of IIb/IIIa
Platelet Inhibition for Stenting (EPISTENT) and the
ESPRIT (Enhanced Suppression of the Platelet IIb/IIIa
Receptor with Integrilin Therapy) trials. In these trials,
improvements in outcomes were seen with adjunctive treat-
ment with abciximab or eptifibatide compared with placebo,
even in the presence of ticlopidine (EPISTENT) or clopi-
dogrel (ESPRIT) (22,23). In particular, in the 2,064-
patient ESPRIT stent PCI study, an additional 35% (p 
0.003) relative risk reduction in the composite end point of
death, MI, and urgent TVR at 30 days was observed with
eptifibatide treatment with concurrent thienopyridine ad-
ministration. These observations should thus help put to
rest the ongoing debate about whether to consider thien-
opyridine and platelet GP IIb/IIIa blockade as therapeutic
competitors or synergistic collaborators in favor of strategies
that use these agents in a concomitant fashion. This is in
accordance with our current understanding of the physiol-
ogy of platelets and the pharmacology of the antiplatelet
agents. Platelet activation, inhibited by thienopyridine ther-
apy, is not affected by platelet GP IIb/IIIa blockade, and
platelet aggregation, suppressed by blockade of the platelet
GP IIb/IIIa integrin, is only modestly inhibited by thien-
opyridine therapy. Even with platelet GP IIb/IIIa blockade,
secretion of vasoactive humors and proinflammatory cyto-
kines can occur; conversely, even with inhibition of the
ADP receptor with thienopyridine therapy, platelet aggre-
gation can occur. The body of evidence thus argues for a
complementary, rather than competitive role for antiplatelet
therapies. To borrow a term coined by the founder of the
Novell Corporation, Ray Noorda, this would be an example
of “coopetition,” both at the pharmacologic and drug
industry levels. Although this is admittedly an inferential
deduction that demands formal testing in randomized
clinical trials, available data would suggest that outcomes are
best optimized by combining aspirin, thienopyridine, and
GP IIb/IIIa antagonist therapies in patients undergoing
stent PCI.
Answers to queries four (optimizing the loading dose)
and five (duration of treatment) are not addressed in this
report, but need to be mentioned to complete the list of
pertinent questions relevant to the positioning of clopi-
dogrel as an adjunct to PCI. Provocative data suggest that
further optimization of the loading dose may be possible
(24), whereas the PCI-CURE and CREDO trials suggest
that continued therapy to one year is of particular benefit in
patients following PCI, a benefit even greater than that
imparted to patients managed with medical therapy alone
(5,6).
In conclusion, there is a compelling and consistent
literature that argues for the use of triple antiplatelet therapy
including aspirin, clopidogrel, and platelet GP IIb/IIIa
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inhibitors in the setting of stent PCI. This broad approach
to inhibiting the platelet at several different loci is effective
in improving the prothrombotic environment created dur-
ing PCI while diminishing the inflammatory response
associated with platelet activation. Triple therapy remains
safe and is associated with a lower incidence of subacute
stent thrombosis, periprocedural MI, TVR, and death.
Based on the current report along with a compilation of
previous work, prudent specific recommendations concern-
ing clopidogrel include the following:
1) Clopidogrel should be started as early as possible (6 h)
before PCI when the anatomy has been defined and the
patient is scheduled for elective PCI.
2) Clopidogrel should be started in an ad hoc fashion
before PCI (but after diagnostic catheterization) in “cath
possible” patients.
3) Both GP IIb/IIIa antagonists and clopidogrel should be
used together and started before PCI, particularly in
higher risk patients; neither is a complete substitute for
the other.
4) Still more information is needed about the optimum
loading dose of clopidogrel preprocedure; a minimum of
300 mg is recommended, with up to 600 mg appearing
reasonable.
5) Clopidogrel treatment should be continued for up to one
year after PCI.
The platelet remains a “black box” that is incompletely
understood; unfortunately, there remain patients with the-
oretically adequate antiplatelet therapy who develop throm-
bosis. Although we have learned much in the recent years
about how to improve our management of patients in the
periprocedural timeframe, more investigation with appro-
priately designed and sized trials will be required to defin-
itively answer the remaining questions and further refine
treatment algorithms.
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